Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Dyserythropoiesis evaluated by RED score and hepcidin/ferritin levels predicts response to erythropoietin in lower risk myelodysplastic syndromes.

Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, Karim Z, Puy H, Alary AS, Ducamp S, Verdier F, Bouilloux C, Rousseau A, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Amé S, Rose C, Lachenal F, Toma A, Pica GM, Carre M, Garban F, Mariette C, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Dreyfus F, Fontenay M.

Haematologica. 2018 Oct 4. pii: haematol.2018.203158. doi: 10.3324/haematol.2018.203158. [Epub ahead of print]

2.

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.

Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Pignon JM, Corm S, Banos A, Mounier C, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouadallah K, Amorin S, Garidi R, Voillat L, Joly B, Celigny PS, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Le Gouill S, Callanan MB; Lymphoma Study Association.

Haematologica. 2019 Jan;104(1):138-146. doi: 10.3324/haematol.2018.191429. Epub 2018 Aug 31.

3.

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.

Lengline E, Drenou B, Peterlin P, Tournilhac O, Abraham J, Berceanu A, Dupriez B, Guillerm G, Raffoux E, de Fontbrune FS, Ades L, Balsat M, Chaoui D, Coppo P, Corm S, Leblanc T, Maillard N, Terriou L, Socié G, de Latour RP.

Haematologica. 2018 Feb;103(2):212-220. doi: 10.3324/haematol.2017.176339. Epub 2017 Nov 23.

4.

Paroxysmal nocturnal hemoglobinuria (PNH) and T cell large granular lymphocyte (LGL) leukemia--an unusual association: another cause of cytopenia in PNH.

Boyer T, Grardel N, Copin MC, Roumier C, Touzart A, Buchdahl AL, Corm S, Peffault de Latour R, Preudhomme C, Terriou L.

Ann Hematol. 2015 Oct;94(10):1759-60. doi: 10.1007/s00277-015-2439-3. Epub 2015 Jul 9. No abstract available.

PMID:
26152552
5.

Endogenous megakaryocytic colonies underline association between megakaryocytes and calreticulin mutations in essential thrombocythemia.

Mondet J, Park JH, Menard A, Marzac C, Carillo S, Pourcelot E, Girodon F, Cabagnols X, Lodé L, Socoro N, Chauvet M, Bulabois CE, Cony-Makhoul P, Corm S, Cahn JY, Mossuz P.

Haematologica. 2015 May;100(5):e176-8. doi: 10.3324/haematol.2014.118927. Epub 2015 Feb 6. No abstract available.

6.

Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study.

Gorin NC, Isnard F, Garderet L, Ikhlef S, Corm S, Quesnel B, Legrand O, Cachanado M, Rousseau A, Laporte JP.

Eur J Haematol. 2013 Oct;91(4):315-21. doi: 10.1111/ejh.12154. Epub 2013 Aug 28.

PMID:
23738686
7.

Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification.

Berthon C, Fontenay M, Corm S, Briche I, Allorge D, Hennart B, Lhermitte M, Quesnel B.

Leuk Res. 2013 May;37(5):573-9. doi: 10.1016/j.leukres.2013.02.001. Epub 2013 Feb 28.

PMID:
23453284
8.

Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.

Sibon D, Cannas G, Baracco F, Prebet T, Vey N, Banos A, Besson C, Corm S, Blanc M, Slama B, Perrier H, Fenaux P, Wattel E; Groupe Francophone des Myélodysplasies.

Br J Haematol. 2012 Mar;156(5):619-25. doi: 10.1111/j.1365-2141.2011.08979.x. Epub 2011 Dec 23.

PMID:
22211483
9.

Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia.

Hochart C, Berthon C, Corm S, Gay J, Cliquennois M, Tricot S, Alfandari S.

Med Mal Infect. 2011 Dec;41(12):652-6. doi: 10.1016/j.medmal.2011.09.014. Epub 2011 Nov 6.

PMID:
22056376
10.

Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study.

Corm S, Roche L, Micol JB, Coiteux V, Bossard N, Nicolini FE, Iwaz J, Preudhomme C, Roche-Lestienne C, Facon T, Remontet L.

Blood. 2011 Oct 20;118(16):4331-7. doi: 10.1182/blood-2011-01-330332. Epub 2011 Aug 17.

11.

Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology.

des Champs-Bro B, Leroy-Cotteau A, Mazingue F, Pasquier F, François N, Corm S, Lemaitre L, Poulain D, Yakoub-Agha I, Alfandari S, Sendid B.

J Clin Pharm Ther. 2011 Apr;36(2):152-60. doi: 10.1111/j.1365-2710.2010.01166.x.

PMID:
21366643
12.

l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.

Domenech C, Thomas X, Chabaud S, Baruchel A, Gueyffier F, Mazingue F, Auvrignon A, Corm S, Dombret H, Chevallier P, Galambrun C, Huguet F, Legrand F, Mechinaud F, Vey N, Philip I, Liens D, Godfrin Y, Rigal D, Bertrand Y.

Br J Haematol. 2011 Apr;153(1):58-65. doi: 10.1111/j.1365-2141.2011.08588.x. Epub 2011 Feb 20.

PMID:
21332712
13.

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC).

N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095.

14.

Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients.

Joha S, Dauphin V, Leprêtre F, Corm S, Nicolini FE, Roumier C, Nibourel O, Grardel N, Maguer-Satta V, Idziorek T, Figeac M, Laï JL, Quesnel B, Etienne G, Guilhot F, Lippert E, Preudhomme C, Roche-Lestienne C.

Leuk Res. 2011 Apr;35(4):448-58. doi: 10.1016/j.leukres.2010.07.012. Epub 2010 Aug 3.

PMID:
20684991
15.

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.

Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, Bourhis JH, Reman O, Turlure P, Contentin N, de Revel T, Rousselot P, Preudhomme C, Bordessoule D, Fenaux P, Terré C, Michallet M, Dombret H, Chevret S, Castaigne S.

J Clin Oncol. 2010 Feb 10;28(5):808-14. doi: 10.1200/JCO.2009.23.2652. Epub 2010 Jan 4.

PMID:
20048183
16.

Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study.

Michallet M, Tulliez M, Corm S, Gardembas M, Huguet F, Oukessou A, Bregman B, Vekhoff A, Ghomari K, Cambier N, Guerci-Bresler A.

Curr Med Res Opin. 2010 Feb;26(2):307-17. doi: 10.1185/03007990903479299.

PMID:
19961284
17.

Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy.

Rea D, Etienne G, Corm S, Cony-Makhoul P, Gardembas M, Legros L, Dubruille V, Hayette S, Mahon FX, Cayuela JM, Nicolini FE.

Leukemia. 2009 Jun;23(6):1193-6. doi: 10.1038/leu.2009.32. Epub 2009 Feb 26. No abstract available.

PMID:
19242496
18.

Fluorescence in situ hybridization characterization of ider(20q) in myelodysplastic syndrome.

Douet-Guilbert N, Laï JL, Basinko A, Gueganic N, Andrieux J, Pollet B, Plantier I, Delattre C, Crépin O, Corm S, Le Bris MJ, Morel F, De Braekeleer M.

Br J Haematol. 2008 Dec;143(5):716-20. doi: 10.1111/j.1365-2141.2008.07436.x. Epub 2008 Oct 21.

PMID:
19036015
19.

[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].

Cony-Makhoul P, Bergeron A, Corm S, Dubruille V, Rea D, Rigal-Huguet F, Nicolini FE.

Bull Cancer. 2008 Sep;95(9):805-11. doi: 10.1684/bdc.2008.0703. French.

20.

Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression?

Deluche L, Joha S, Corm S, Daudignon A, Geffroy S, Quief S, Villenet C, Kerckaert JP, Laï JL, Preudhomme C, Roche-Lestienne C.

Genes Chromosomes Cancer. 2008 Dec;47(12):1110-7. doi: 10.1002/gcc.20611.

PMID:
18767145
21.

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L, Coutre S, Corm S, Hamerschlak N, Tang JL, Hochhaus A, Khoury HJ, Brümmendorf TH, Michallet M, Rege-Cambrin G, Gambacorti-Passerini C, Radich JP, Ernst T, Zhu C, Van Tornout JM, Talpaz M.

Leukemia. 2008 Dec;22(12):2176-83. doi: 10.1038/leu.2008.221. Epub 2008 Aug 28.

PMID:
18754032
22.

Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma.

Corm S, Berthon C, Imbenotte M, Biggio V, Lhermitte M, Dupont C, Briche I, Quesnel B.

Leuk Res. 2009 Mar;33(3):490-4. doi: 10.1016/j.leukres.2008.06.014. Epub 2008 Jul 18.

PMID:
18639339
23.

Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy.

Richebourg S, Eclache V, Perot C, Portnoi MF, Van den Akker J, Terré C, Maareck O, Soenen V, Viguié F, Laï JL, Andrieux J, Corm S, Roche-Lestienne C; Fi-LMC Group.

Cancer Genet Cytogenet. 2008 Apr 15;182(2):95-102. doi: 10.1016/j.cancergencyto.2008.01.005.

PMID:
18406870
24.

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM.

Leukemia. 2008 Jun;22(6):1200-6. doi: 10.1038/leu.2008.84. Epub 2008 Apr 10.

PMID:
18401416
25.

BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism.

Liu J, Joha S, Idziorek T, Corm S, Hetuin D, Philippe N, Preudhomme C, Quesnel B.

Leukemia. 2008 Apr;22(4):791-9. doi: 10.1038/leu.2008.3. Epub 2008 Jan 24.

PMID:
18216868
26.

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.

Roche-Lestienne C, Deluche L, Corm S, Tigaud I, Joha S, Philippe N, Geffroy S, Laï JL, Nicolini FE, Preudhomme C; Fi-LMC group.

Blood. 2008 Apr 1;111(7):3735-41. doi: 10.1182/blood-2007-07-102533. Epub 2008 Jan 17.

27.

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.

Nicolini FE, Hayette S, Corm S, Bachy E, Bories D, Tulliez M, Guilhot F, Legros L, Maloisel F, Kiladjian JJ, Mahon FX, Lê QH, Michallet M, Roche-Lestienne C, Preudhomme C.

Haematologica. 2007 Sep;92(9):1238-41.

28.

Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation.

Corm S, Renneville A, Rad-Quesnel E, Grardel N, Preudhomme C, Quesnel B.

Leukemia. 2007 Nov;21(11):2376-7. Epub 2007 Jun 7. No abstract available.

PMID:
17554376
29.

The prognosis impact of BCR-ABL P-loop mutations: worse or not worse?

Nicolini FE, Corm S, Lê QH, Roche-Lestienne C, Preudhomme C.

Leukemia. 2007 Feb;21(2):193-4. No abstract available.

PMID:
17251899
30.

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).

Nicolini FE, Corm S, Lê QH, Sorel N, Hayette S, Bories D, Leguay T, Roy L, Giraudier S, Tulliez M, Facon T, Mahon FX, Cayuela JM, Rousselot P, Michallet M, Preudhomme C, Guilhot F, Roche-Lestienne C.

Leukemia. 2006 Jun;20(6):1061-6.

PMID:
16642048
31.

Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.

Corm S, Biggio V, Roche-Lestienne C, Laï JL, Yakoub-Agha I, Philippe N, Nicolini FE, Facon T, Preudhomme C.

Leukemia. 2005 Nov;19(11):1991-2. No abstract available.

PMID:
16151468
32.
33.

Efficient generation of antileukemic autologous T cells by short-term culture and gamma-irradiation of myeloid leukemic cells.

Vereecque R, Saudemont A, Depil S, Corm S, Andrieux J, Soenen-Cornu V, Quesnel B.

Cancer Immunol Immunother. 2004 Sep;53(9):793-8. Epub 2004 Apr 20.

PMID:
15098140

Supplemental Content

Support Center